439803-63-1

Upstream product

• 73-40-5 2-amino-6-hydroxypurine 
• 10310-21-1 2-Amino-6-chloropurin 
• 106-47-8 4-chloro-aniline 
• 5451-40-1 2,6-dichloro-7H-purine 
• 97965-44-1 2-acetamido-9-acetyl-6-chloropurine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 190655-15-3 2-chloro-6-(4-chloro-phenyl-amino)-9-ethyl-9H-purine 
• 1236432-02-2 N-(4-chlorophenyl)-2-morpholino-9H-purin-6-amine 
• 1236431-82-5 N-(4-chlorophenyl)-2-(piperazin-1-yl)-9H-purin-6-amine 
• 1236432-24-8 N-(4-chlorophenyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-9H-purin-6-amine 
• 1338808-01-7 2,6-di-p-chloroanilinepurine 
• 1338808-02-8 2-p-methoxyaniline-6-p-chloroanilinepurine 
• 1338807-99-0 2-aniline-6-p-chloroanilinepurine 

Relevant academic research and scientific papers

Syntheses and biological evaluation of novel hydroxamic acid derivatives containing purine moiety as histone deacetylase inhibitors

The novel hydroxamates containing purine scaffold were designed, synthesized and screened for their biological activities as histone deacetylase (HDAC) inhibitors. Some of them exhibited excellent acti-HDACs activities and antiproliferative activities, th

Microwave assisted synthesis of 2,6-substituted aromatic-aminopurine derivatives

A series of novel 2, 6-diaromatic-aminopurines (6a-6t) have been synthesized from guanine and characterized fully. The effects of different catalysts on the N-alkylation of 2-position of purine ring were discussed.

SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES

The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.

Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase

We report here the discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase by adopting a strategy integrating focused combinatorial library design, virtual screening, chemical synthesis, and bioass

Novel potent inhibitors of A. thaliana cytokinin oxidase/dehydrogenase

The synthesis of a new group of 2-X-6-anilinopurines, including compounds with potential cytokinin-like activities, with various substitutions (X = H, halogen, amino, methylthio or nitro) on the phenyl ring is described. The prepared compounds have been characterized using standard physico-chemical methods, and the influence of individual substituents on biological activity has been compared in three different bioassays, based on the stimulation of tobacco callus growth, retention of chlorophyll in excised wheat leaves and the dark induction of betacyanin synthesis in Amaranthus cotyledons. The biological activity of the prepared compounds was also assessed in receptor assays, in which the ability of the compounds to activate the cytokinin receptors AHK3 and AHK4/CRE1 was studied. Finally, the interactions of the compounds with the Arabidopsis cytokinin oxidase/dehydrogenase AtCKX2 (heterologously expressed) were investigated. Systematic testing led to the identification of two very potent inhibitors of AtCKX2: 2-chloro-6-(3-methoxyphenyl)aminopurine and 2-fluoro-6-(3-methoxyphenyl)aminopurine.

Novel purine derivatives, preparation method and use as medicines

The use of purine derivatives of formula (I): as cdk kinase inhibitors for the prevention and treatment of fungal infections. Also disclosed are novel methods and intermediates for the production of compounds of formula I, as well as pharmaceutical compositions containing said compounds.

NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY

The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest ar